Market Place
Sourcing Support
Cogent Bio`s Presentation at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
GLOBENEWSWIRE
Cogent Bio Announces Summit Trial Result for Systemic Mastocytosis
09 Dec 2024 //
GLOBENEWSWIRE
Cogent`s Bezuclastinib Data Positive in Systemic Mastocytosis
08 Dec 2024 //
GLOBENEWSWIRE
Cogent Bio Reports Business Highlights & Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Cogent Biosciences Presents Bezuclastinib Data at ASH 2024
05 Nov 2024 //
GLOBENEWSWIRE
Cogent Biosciences Expands Pipeline into KRAS
23 Oct 2024 //
GLOBENEWSWIRE
Cogent Biosciences Completes Phase 3 PEAK Trial Enrollment for GIST
03 Sep 2024 //
GLOBENEWSWIRE
Cogent Biosciences Reports Q2 2024 Results And Business Highlights
06 Aug 2024 //
GLOBENEWSWIRE
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2
27 Jun 2024 //
GLOBENEWSWIRE
Cogent Reports Additional Bezuclastinib Data In NonAdvSM
14 Jun 2024 //
GLOBENEWSWIRE
Cogent Bezuclastinib Peak Lead-In: Gist Phase 3 Positive At Asco
23 May 2024 //
GLOBENEWSWIRE
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
23 May 2024 //
GLOBENEWSWIRE
Cogent Biosciences Reports First Quarter 2024 Financial Results
07 May 2024 //
GLOBENEWSWIRE
Cogent Biosciences Presents Novel ErbB2 Inhibitor Data
09 Apr 2024 //
GLOBENEWSWIRE
Cogent Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
Cogent Announces Positive Part 1b Data from Trial Evaluating Bezuclastinib
22 Feb 2024 //
GLOBENEWSWIRE
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
14 Feb 2024 //
GLOBENEWSWIRE
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvSM
05 Feb 2024 //
GLOBENEWSWIRE
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib
09 Jan 2024 //
GLOBENEWSWIRE
Cogent Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Cogent Announces Positive Data from Phase 2 APEX Trial Evaluating Bezuclastinib
11 Dec 2023 //
GLOBENEWSWIRE
Cogent Announces Positive Data from Phase 2 Trial Evaluating Bezuclastinib
09 Dec 2023 //
GLOBENEWSWIRE
Cogent Bio Presents New Preclinical Data Highlighting Selectivity of ErbB2
07 Dec 2023 //
GLOBENEWSWIRE
Cogent Biosciences to Host Investor Webcast on December 11
04 Dec 2023 //
GLOBENEWSWIRE
Cogent Announces Poster Presentations at San Antonio Breast Cancer Symposium
29 Nov 2023 //
GLOBENEWSWIRE
Cogent Reports Recent Business Highlights & Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Cogent Bio Presents Preclinical Data Highlighting Precision Oncology Pipeline
14 Oct 2023 //
GLOBENEWSWIRE
Cogent Biosciences Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
09 Jun 2023 //
PRESS RELEASE
Cogent follows ASCO data drop for KIT inhibitor with upsized $150M public stock offering
07 Jun 2023 //
ENDPTS
Cogent Biosciences Announces Participation in Jefferies Healthcare Conference
07 Jun 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Proposed Public Offering of Common Stock
06 Jun 2023 //
GLOBENEWSWIRE
Cogent Announces Pricing of Upsized Public Offering of Shares of Common Stock
06 Jun 2023 //
GLOBENEWSWIRE
Cogent Bio Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial
03 Jun 2023 //
GLOBENEWSWIRE
Cogent to Host Webcast to Discuss Lead-In Data Being Presented at ASCO
23 May 2023 //
GLOBENEWSWIRE
Cogent Biosciences Reports Recent Business Highlights and1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Cogent Presents Preclinical at AACR highlighting Precision Therapy Pipeline
17 Apr 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
12 Apr 2023 //
GLOBENEWSWIRE
Cogent Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
14 Mar 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
01 Feb 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib
09 Jan 2023 //
GLOBENEWSWIRE
Cogent Biosciences Announces Presentation at the 41st J.P. Morgan Conference
05 Jan 2023 //
GLOBENEWSWIRE
Cogent touts data on small subset of patients in bid to compete with Blueprint
12 Dec 2022 //
ENDPTS
Cogent Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial
11 Dec 2022 //
GLOBENEWSWIRE
Cogent Biosciences to Host Investor Webcast to Discuss Clinical Data at ASH
05 Dec 2022 //
BIOSPACE
Cogent Biosciences Appoints Rachael Easton VP, Head of Clinical Development
28 Nov 2022 //
GLOBENEWSWIRE
Cogent Biosciences Appoints Rachael Easton Head of Clinical Development
28 Nov 2022 //
GLOBENEWSWIRE
Cogent Biosciences Reports Recent Business Highlights and 3Q 2022 FYR
14 Nov 2022 //
GLOBENEWSWIRE
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
09 Nov 2022 //
GLOBENEWSWIRE
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th (ASH)
03 Nov 2022 //
GLOBENEWSWIRE
Cogent to Showcase Precision Therapy Pipeline at EORTC-NCI-AACR Annual Meeting
26 Oct 2022 //
GLOBENEWSWIRE
Cogent Biosciences (NASDAQ:COGT) Shares Up 3.4%
21 Aug 2022 //
DEFENSEWORLD
Cogent Biosciences Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
PRESS RELEASE
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
16 Jun 2022 //
GLOBENEWSWIRE
Cogent Biosciences Announces Proposed Public Offering of Common Stock
13 Jun 2022 //
GLOBENEWSWIRE
Cogent Announces Pricing of Upsized Public Offering of Shares of Common Stock
13 Jun 2022 //
GLOBENEWSWIRE
Cogent Bio Announces Positive Initial Data from Ongoing PII APEX Trial
10 Jun 2022 //
GLOBENEWSWIRE
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
06 Jun 2022 //
GLOBENEWSWIRE
Cogent Biosciences Announces Annual Meeting of Stockholders
02 Jun 2022 //
GLOBENEWSWIRE
Cogent Biosciences Announces Presentation at EHA
12 May 2022 //
GLOBENEWSWIRE
